- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LOTUS PHARMACEUTICALS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STADA ARZNEIMITTEL | - | - | CapVest Partners LLP: CapVest schließt Übernahme der Mehrheitsanteile an Stada ab | CapVest Partners LLP ("CapVest"), eine weltweit führende Investmentgesellschaft, gibt heute den Abschluss der Übernahme der Mehrheitsanteile an der STADA Arzneimittel AG ("STADA" oder das "Unternehmen")... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 65,50 | +1,02 % | H.C. Wainwright reiterates Ionis Pharmaceuticals stock rating at buy | ||
| CSPC PHARMA | 1,068 | -1,16 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - GRANT OF AWARDED SHARES PURSUANT TO THE 2018 SHARE AWARD SCHEME OF THE COMPANY | ||
| SELLAS LIFE SCIENCES | 3,520 | -1,81 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 18,910 | -1,74 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 21,490 | +0,37 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3%... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 471,80 | 0,00 % | Wolfe Research bestätigt "Peerperform" für Madrigal - M&A-Fantasie treibt Aktie | ||
| OPUS GENETICS | 3,870 | -1,78 % | Opus Genetics, Inc.: Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update | - Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal experts with additional data expected mid-year 2026 - - Reauthorization of... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets | Northvale, New Jersey--(Newsfile Corp. - April 2, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 4,780 | -0,42 % | Savara Inc.: Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | -- EMA Review of MOLBREEVI MAA Has Now Initiated, Decision Expected in Q1 2027 -- -- MOLBREEVI Biologics License Application (BLA) is Currently Under Priority Review with the U.S. Food and Drug... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 2,140 | -0,93 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update | NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 0,900 | 0,00 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA65564N1006 Westgold Metals Corp. 02.04.2026 CA96033F1053 Westgold Metals Corp. 07.04.2026 Tausch 1:1BMG0403V2062 APAC... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 1,950 | 0,00 % | NovaBay firmiert in Stablecoin Development Corp um und vergibt Aktienpakete an Management | ||
| CIPHER PHARMACEUTICALS | 11,300 | 0,00 % | Cipher Pharmaceuticals übertrifft Gewinnerwartungen, verfehlt aber Umsatzziel | ||
| NEURIZON THERAPEUTICS | 0,041 | +3,80 % | NEURIZON THERAPEUTICS LIMITED: Section 708A Cleansing Statement |
Das Unternehmen LOTUS PHARMACEUTICALS INC kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOTUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.